Immunic, Inc. · NASDAQ:IMUX

Immunic — Technical Presentation (May 2023)

61 slides from Immunic's technical presentation, May 4, 2023

  1. Slide 1: Changing Paradigms: IMU-856 Celiac Disease Clinical Phase 1b Results

    Changing Paradigms IMU-856: Celiac Disease Clinical Phase 1b Results NASDAQ: IMUX | May 4, 2023

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities

  3. Slide 3: Today's Highlights

    Today’s Highlights Positive Phase 1b Results of IMU-856 in Celiac Disease Regeneration and protection of the gut wall proven for the first time in patients, establishing a new concept for healthy gut in gastrointestinal disorders Consistent clinical benefit seen across four dimensions of clinical ou

  4. Slide 4: IMU-856 could become a game changer in the way we treat gastrointestinal diseases

    IMU-856 could become a game changer in the way we treat gastrointestinal diseases.

  5. Slide 5: Once-Daily, Oral IMU-856 Aims to Regenerate the Gut Wall and Barrier Function

    Once-Daily, Oral IMU-856 Aims to Regenerate the Gut Wall and Barrier Function by a New Epigenetic Mechanism Damaged Gut Wall Healthy Gut Wall Bowel lumen Bowel lumen IMU-856: antigens, microbiome, nutrients antigens, microbiome, nutrients § Epigenetic modulator aimed to regenerate gut wall and IMU-8

  6. Slide 6: IMU-856 Enhances the Natural Regenerative Process in the Gut

    IMU-856 Enhances the Natural Regenerative Process in the Gut Gut wall renewal is a normal physiological process Asymmetric cell division renews stem cells 1. Regeneration begins in the crypts, where and regenerates the gut wall intestinal stem cells are located 2. Stem cells undergo asymmetric divis

  7. Slide 7: IMU-856 is a completely new approach for gastrointestinal diseases

    IMU-856 is a completely new approach for the treatment of gastrointestinal diseases by restoring a healthy gut by renewal of the gut wall.

  8. Slide 8: First Proof-of-Concept for Gastrointestinal Disorders in Celiac Disease

    First Proof-of-Concept for Gastrointestinal Disorders in Celiac Disease Celiac Disease is a Serious Life-Long Disease Celiac disease is a multifactorial, complex autoimmune disease caused by an immune reaction against a degradation product of gluten and is strongly associated with specific HLA glute

  9. Slide 9: IMU-856 Addresses Two Key Pathological Aspects of Celiac Disease

    IMU-856 Addresses Two Key Pathological Aspects of Celiac Disease IMU-856 Mode of Action Orally available and systemically acting small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium Celiac Dise

  10. Slide 10: Celiac Disease Currently Has No Adequate Treatment Options

    Celiac Disease Currently Has No Adequate Treatment Options § Two million patients diagnosed with celiac disease in the 10 mg of gluten is the total limit for all US; more than one million more undiagnosed[1,2] foods combined for the entire day. § Most studies report between 24% and 47%[3-8] of patie

  11. Slide 11: Positive Effects in Main Four Dimensions of Clinical Outcome

    IMU-856 Shows Positive Effects in Main Four Dimensions of Clinical Outcome in Celiac Disease Patients IMU-856 effectively reduces IMU-856 reduces/reverses gluten-induced intestinal damage, gluten-induced symptoms as measured by villous height Protect Improve reported by patients Gut Patients’ Archit

  12. Slide 12: Trial Design

    Trial Design Phase 1b Clinical Trial of IMU-856

  13. Slide 13: Trial Design: Phase 1b Clinical Trial of IMU-856

    Trial Design Phase 1 Clinical Trial of IMU-856 PART A PART B PART C Evaluation of single Evaluation of multiple Evaluation of patients with ascending doses (SAD) ascending doses (MAD) celiac disease receiving 28-day Healthy human subjects Healthy human subjects randomized treatment of IMU-856 or pla

  14. Slide 14: Phase 1b Clinical Trial in Celiac Disease: Gluten Challenge Design

    Phase 1b Clinical Trial of IMU-856 in Celiac Disease Designed as a Gluten Challenge Trial Flow Chart of Part C in Celiac Disease Proof-of-Concept Study Day 1-28: Treatment IMU-856/placebo § Part C planned to include a well-controlled celiac disease patient population § 100% seronegative patients (in

  15. Slide 15: Patients Per Treatment Group

    Patients Per Treatment Group Randomized/Completed N=43/35 80 mg IMU-856 160 mg IMU-856 Placebo Assigned/Completed Assigned/Completed Assigned/Completed N=14/11 N=15/13 N=14/11 Day 14 BL/Day 29 Day 14 BL/Day 29 Day 14 BL/Day 29 IL-2; N=14 EGD; N=11 IL-2; N=12 EGD; N=13 IL-2; N=13 EGD; N=11 Reasons fo

  16. Slide 16: Distribution of Q-MARSH Histology Score at Baseline

    Distribution of Q-MARSH Histology Score at Baseline Approximately 60% of IMU-856 Treated Patients Already in FDA Required Phase 2/3 Population Category IMU-856 80 mg IMU-856 160 mg All Active All Placebo § Inclusion criteria representing well-controlled (N=14) (N=15) (N=29) (N=14) celiac disease: Q-

  17. Slide 17: Protects Gut Architecture

    Protects Gut Architecture Phase 1b Clinical Trial of IMU-856

  18. Slide 18: Histological Hallmarks of Celiac Disease

    Histological Hallmarks of Celiac Disease A Well-Controlled Celiac Disease B Ongoing Active Celiac Disease (OACD) § Villi with normal appearance § Villous height:Crypt depth ratio decreases Gluten Exposure Kamboj et al., Clinical and Translational Gastroenterology (2017) 8, e114 18 | © Immunic, Inc.

  19. Slide 19: IMU-856 Protects Villous Height as Compared to Placebo

    IMU-856 Protects Villous Height as Compared to Placebo Absolute change in villous height (μm) between Baseline and Day 29 Day 1-28: Treatment IMU-856/placebo 0 Day 14-28: Gluten challenge with 6 g/daily -10 Mean -20.9 Mean -22.5 SD 34.8 SD 51.1 Baseline: Visit 6 / Day 29: -20 EGD with biopsy EGD wit

  20. Slide 20: Individual Patient Data for Changes in Villous Height

    Individual Patient Data for Changes in Villous Height Dose-Dependent Shift in Histological Protection From Placebo to 160 mg of IMU-856 Relative change from Baseline in villous height Waterfall plot for relative changes in villous height (in % of baseline) for individual patients. Disease Analysis S

  21. Slide 21: Staging of Celiac Disease: Q-Marsh Histological Scores

    Staging of Celiac Disease: Q-Marsh Histological Scores Schematic Depiction of Marsh-Oberhuber Grades 0 1 2 3a 3b 3c Villi reduced in height Crypts enlarged in depth Healthy mucosa Well-Controlled CelD Ongoing Active CelD § Little malabsorption § Minimal malabsorption § Extensive § No villous atrophy

  22. Slide 22: Shows Signal Preventing Histological Damage (Q-Marsh)

    IMU-856 Shows Signal Preventing Histological Damage (Q-Marsh) Change in Q-MARSH between Baseline and Day 29 Deterioration/improvement defined as at least a decrease/increase of 1 category in Q-MARSH score on Day 29 as compared to Baseline Marsh Villous Oberhuber height:Crypt Deterioration Improvemen

  23. Slide 23: Improves Patients' Symptoms

    Improves Patients’ Symptoms Phase 1b Clinical Trial of IMU-856

  24. Slide 24: Fewer Symptoms After First Day of Gluten Challenge

    IMU-856 Treated Patients Have Fewer Symptoms After First Day of Gluten Challenge Than Placebo Patients (on Day 14) Mean change in symptoms from last day before gluten challenge to first day of gluten challenge 1 0.9 Mean 0.8 Mean 0.8 Mean 0.8 SD 1.2 SD 1.1 SD 1.4 0.8 Mean group change in CDSD score

  25. Slide 25: Treated Patients Recover From Bloating Symptoms

    IMU-856 Treated Patients Recover From Bloating Symptoms on Continued Treatment During Gluten Challenge Bloating: Mean change from Day 13 to Day 14 Bloating: Mean change from Day 14 to Day 29 1 0.8 Mean 0.5 0.6 Mean 0.4 Mean group change in CDSD score SD 0.7 SD 0.9 0.4 Mean 0.1 0.2 SD 0.8 Symptoms Fe

  26. Slide 26: Treated Patients Recover From Tiredness Symptoms

    IMU-856 Treated Patients Recover From Tiredness Symptoms on Continued Treatment During Gluten Challenge Tiredness: Mean change from Day 13 to Day 14 Tiredness: Mean change from Day 14 to Day 29 1 Mean 0.8 SD 1.1 0.8 Mean group change in CDSD score 0.6 Mean 0.3 0.4 SD 0.6 Mean 0.1 0.2 SD 0.64 Symptom

  27. Slide 27: Biomarker Response

    Biomarker Response Phase 1b Clinical Trial of IMU-856

  28. Slide 28: IMU-856 Dampens Acute IL-2 Immune Response

    IMU-856 Dampens Acute IL-2 Immune Response on First Day of Gluten Challenge Mean absolute change and maximum change in serum IL-2 (in pg/mL) from pre-gluten to 4 hours post- gluten on first day of gluten challenge Luminex® Test System SIMOA® Test System Max 274.3 Max 35.7 IMU-856 dampens gluten-indu

  29. Slide 29: IMU-856 Shows Signal for Improving Citrulline

    IMU-856 Shows Signal for Improving Citrulline Biomarker Reflecting the Health Status and Function of Enterocytes Mean change from Baseline to Day 14 Mean change from Baseline to Day 29 Citrulline is a non-essential amino 8 Mean 6.1 acid that is mainly produced by the SD 5.9 enterocyte and, hence, th

  30. Slide 30: Enhances Nutrient Absorption

    Enhances Nutrient Absorption Phase 1b Clinical Trial of IMU-856

  31. Slide 31: Enhanced Uptake of Vitamin B12

    IMU-856 Shows Enhanced Uptake of Vitamin B12 Mean change from Baseline to Day 29 in vitamin B12 (pmol/L) 80 Mean 74.2 60 SD 99.9 Serum vitamin B12 (pmol/L) 40 Mean 45.8 SD 94.4 20 0 -20 Mean -31.0 SD 68.8 -40 Placebo (N=11) IMU-856 80 mg (N=11) IMU-856 160 mg (N=13) SD: standard deviation 31 | © Imm

  32. Slide 32: Enhanced Uptake of Zinc

    IMU-856 Shows Enhanced Uptake of Zinc Mean change from Baseline to Day 29 in zinc (µmol/L) 1 0.8 Mean 0.9 SD 2.1 0.6 0.4 Serum zinc (µmo/L) 0.2 Mean 0.3 SD 1.4 0 -0.2 -0.4 -0.6 Mean -0.9 -0.8 SD 2.1 -1 Placebo (N=11) IMU-856 80 mg (N=11) IMU-856 160 mg (N=13) SD: standard deviation 32 | © Immunic, I

  33. Slide 33: Amelioration of Gluten-Induced Iron Malabsorption – Ferritin Levels

    IMU-856 Shows Amelioration of Gluten-Induced Iron Malabsorption – Ferritin Levels Mean Change from Baseline to Day 29 in Ferritin (µg/L) 0 -5 Mean -11.4 -10 SD 20.2 Mean -16.0 -15 SD 66.0 Serum ferritin (µg/L) -20 -25 -30 -35 Mean -40.3 SD 37.9 -40 -45 Placebo (N=11) IMU-856 80 mg (N=11) IMU-856 160

  34. Slide 34: Improvement in Red Blood Cell Function

    IMU-856 Shows Improvement in Red Blood Cell Function as a Consequence of Improved Iron Absorption Mean Change from Baseline to Day 29 in MCHC (g/L) 8 6 Mean 6.2 MCHC is a measure of the SD 12.4 4 concentration of hemoglobin in red blood cells. Serum MCHC (g/L) 2 Mean 0.4 SD 6.6 Since hemoglobin is t

  35. Slide 35: Positive Effects in Main Four Dimensions of Clinical Outcome

    IMU-856 Shows Positive Effects in Main Four Dimensions of Clinical Outcome in Celiac Disease Patients IMU-856 effectively reduces IMU-856 reduces/reverses gluten-induced intestinal damage, gluten-induced symptoms as measured by villous height Protect Improve reported by patients Gut Patients’ Archit

  36. Slide 36: Safety and Pharmacokinetics

    Safety and Pharmacokinetics Phase 1b Clinical Trial of IMU-856

  37. Slide 37: Overall Summary of Treatment Emergent Adverse Events

    Overall Summary of Treatment Emergent Adverse Events Treatment IMU-856 safe and Category IMU-856 80 mg IMU-856 160 mg All Active All Placebo (N=14) (N=15) (N=29) (N=14) well-tolerated despite a more Subjects with TEAEs, n (%) 13 (92.9) 13 (86.7) 26 (89.7) 10 (71.4) severe patient Subjects with mild

  38. Slide 38: Disease-Related TEAEs Associated With Ongoing Active Celiac Disease Patients

    Disease-Related TEAEs Associated With High Number of Ongoing Active Celiac Disease Patients in IMU-856 Treatment Group TEAEs regularly associated with celiac disease and occurring in more than 10 % of all subjects Number of subjects (%) [number of TEAEs reported] § Higher incidence of celiac disease

  39. Slide 39: No Change in Neutrophils as Compared to Placebo

    No Change in Neutrophils as Compared to Placebo Laboratory Values Over Time Individual Laboratory Values Hematology – Neutrophils Hematology – Neutrophils 39 | © Immunic, Inc. | May/04/2023

  40. Slide 40: No Hy's Law Cases

    No Hy’s Law Cases Bilirubin vs. ALT Showed Bilirubin vs. AST Showed No Evidence of DILI Potential No Evidence of DILI Potential ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; DILI: drug-induced liver injury; BIL: Bilirubin; ULN: Upper Limit of Normal 40 | © Immunic, Inc. | May/04/20

  41. Slide 41: No Clinically Relevant Changes of QTcF Interval

    No Clinically Relevant Changes of QTcF Interval 12-Lead ECGs Over Time Individual 12-Lead ECGs QTcF Interval QTcF Interval hi m hi_f hi_f hi m hi m hi_f hi_f hi m ECG: electrocardiogram; QTcF: Fridericia’s correction formula for QT intervall 41 | © Immunic, Inc. | May/04/2023

  42. Slide 42: Pharmacokinetics: Trough Levels After Multiple Dosing

    Pharmacokinetics: Trough Levels After Multiple Dosing IMU-856 mean trough levels (ng/mL) 200 Day 8 180 Mean Plasma Concentration (ng/mL) 160 Value IMU-856 80 mg IMU-856 160 mg 140 (Mean) 120 Cmax 100 354.5 765.6 (ng/mL) 80 60 Tmax 1.9 1.5 40 (hr) 20 AUC 0-tlast 0 1568 3613 Day 1 Day 8 Day 14 Day 15

  43. Slide 43: Positive Effects in Main Four Dimensions of Clinical Outcome

    IMU-856 Shows Positive Effects in Main Four Dimensions of Clinical Outcome in Celiac Disease Patients Final phase 1b celiac disease data consistently shows beneficial effects for IMU-856 over placebo: § Prevents histological damage § Consistent benefits on symptoms over placebo § Dose-linear respons

  44. Slide 44: Intestinal Barrier Function is a Therapeutic Target Beyond Celiac Disease

    Intestinal Barrier Function is a Therapeutic Target Beyond Celiac Disease Compromised intestinal barrier function has been associated not only with celiac disease but with a number of disease states, both intestinal and systemic Crohn’s disease: low bowel permeability has better IBS-D: bowel permeab

  45. Slide 45: IMU-856 Could Elevate Standard-of-Care Across Multiple GI Diseases

    IMU-856 Could Elevate the Standard-of-Care Across Multiple Gastrointestinal Diseases With Histologic Damage Combination Therapy in Multiple GI Diseases Multi-million patients in US Ulcerative Colitis ~1 million patients in US§ Potential for Crohn’s Disease complementary / ~1 million patients in US §

  46. Slide 46: IMU-856 Could Become a Game Changer for Gastrointestinal Disorders

    IMU-856 Could Become a Game Changer for the Treatment of Gastrointestinal Disorders IMU-856 is poised to be a potential paradigm shift in how to treat gastrointestinal diseases. Dozens of endpoints were investigated in this small exploratory trial and all demonstrated that IMU-856 has a beneficial e

  47. Slide 47: Q&A Session

    Q&A Session Phase 1b Clinical Trial of IMU-856

  48. Slide 48: Thank You!

    Thank You! Immunic, Inc. Immunic AG 1200 Avenue of the Americas Lochhamer Schlag 21 New York City, NY 10036 82166 Gräfelfing (Munich) USA Germany Jessica Breu Head of IR & Communications Immunic Australia Pty. Ltd. Phone: +49-89-2080477-09 Melbourne Email: ir@imux.com Australia Web: www.imux.com 48

  49. Slide 49: Appendix

    Appendix Phase 1b Clinical Trial of IMU-856

  50. Slide 50: Pathophysiology of Malabsorption in Celiac Disease

    Pathophysiology of Malabsorption in Celiac Disease § The small intestine measures approximately 6 m in length § The surface area of the small intestine is significantly enhanced by the presence of villi and microvilli by up to 600-fold § One of the main functions of villi is to absorb nutrients from

  51. Slide 51: Patient Demographics

    Patient Demographics IMU-856 80 mg IMU-856 160 mg All Active All Placebo Parameter (N=14) (N=15) (N=29) (N=14) Mean age (years) 43.1 40.9 42.0 43.4 Female N (%) 8 (57.1) 10 (66.7) 18 (62.1) 11 (78.6) White 14 (100) 15 (100) 29 (100) 14 (100) Race N (%) Other 0 0 0 0 Mean height (cm) 173.86 169.53 17

  52. Slide 52: Villous Height Results Stratified by Baseline Disease Severity

    Villous Height Results Stratified by Baseline Disease Severity Baseline Disease Baseline Disease Severity by Baseline Mean Absolute Mean Relative Change Severity Treatment Arm N[1] Villous Height[1] Change to Day 29 to Day 29 (Q-Marsh) (Q-Marsh) (in µm) (in µm) Placebo pooled 10 (11) 383.6 -56.6 -14

  53. Slide 53: Signal Preventing Histological Damage During Gluten Challenge (Vh:Cd)

    IMU-856 Shows Signal Preventing Histological Damage During Two-Week, 6 g Gluten Challenge (Vh:Cd) Absolute change in Vh:Cd between Baseline and Day 29 IMU-856 80 mg IMU-856 160 mg All Active All Placebo (N=11) (N=13) (N=24) (N=11) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Absolute Change Vh:Cd -0.19 (

  54. Slide 54: Patient Reported Outcomes: Celiac Disease Symptom Diary (CDSD)

    Patient Reported Outcomes: Celiac Disease Symptom Diary (CDSD) CDSD Version 2.1© Description § The CDSD is a daily patient reported outcome measurement assessing the presence or absence of a broad range of symptoms typical for celiac disease § Phase 1b trial of IMU-856: – On Day 1: CDSD Questionnair

  55. Slide 55: Protecting Against Acute Gluten-Induced Symptoms on First Day

    IMU-856 Shows Signal Protecting Against Acute Gluten-Induced Symptoms on First Day of Gluten Challenge Mean change from last day before gluten challenge to first day of gluten challenge IMU-856 80 mg IMU-856 160 mg All Active All Placebo Symptom (N=13) (N=13) (N=26) (N=12) Mean (SD) Mean (SD) Mean (

  56. Slide 56: Protecting Against Chronic Gluten-Induced Symptoms

    IMU-856 Shows Signal Protecting Against Chronic Gluten-Induced Symptoms Mean change from Day 13 to Day 14 Mean change from Day 14 to Day 29 Bloating Tiredness Bloating Tiredness N N Mean (SD) Mean (SD) Mean (SD) Mean (SD) IMU-856 80 mg 13 0.3 (0.85) 0.2 (0.60) 9 -0.4 (1.01) -0.1 (0.33) IMU-856 160 m

  57. Slide 57: Patient Reported Outcomes: Impact Of Celiac Disease Symptom Questionnaire

    Patient Reported Outcomes: Impact Of Celiac Disease Symptom Questionnaire (ICDSQ©) Description § Questionnaire is assessed weekly and suggested as complement to the Celiac Disease Symptom Diary (CDSD)[1]: – Baseline (Day 1) – Visit 5 (Day 22) § Schedule of assessment phase 1b – Visit 2 (day 8) – Vis

  58. Slide 58: Ameliorates Negative Gluten-Induced Impact on Daily Activities

    IMU-856 Ameliorates Negative Gluten-Induced Impact on Daily Activities Daily Activities, Mean Change Baseline to Day 14 Day 14 to Day 22 Day 14 to Day 29 Mean Change Mean Change Mean Change N N N Mean (SD) Mean (SD) Mean (SD) IMU-856 80 mg 14 0.089 (0.362) 11 0.091 (0.573) 10 0.000 (0.425) IMU-856 1

  59. Slide 59: Non-Inferior to Placebo Regarding Impact on Social Activities

    IMU-856 Non-Inferior to Placebo Regarding Negative Gluten- Induced Impact on Social Activities Social Activities, Mean Change Baseline to Day 14 Day 14 to Day 22 Day 14 to Day 29 Mean Change Mean Change Mean Change N N N Mean (SD) Mean (SD) Mean (SD) IMU-856 80 mg 14 -0.095 (0.275) 11 0.182 (0.721)

  60. Slide 60: Ameliorates Negative Gluten-Induced Impact on Emotional Well-Being

    IMU-856 Ameliorates Negative Gluten-Induced Impact on Emotional Well-Being Emotional Well-Being, Mean Change Baseline to Day 14 Day 14 to Day 22 Day 14 to Day 29 Mean Change Mean Change Mean Change N N N Mean (SD) Mean (SD) Mean (SD) IMU-856 80 mg 14 -0.014 (0.183) 11 0.105 (0.294) 9 -0.044 (0.088)

  61. Slide 61: Ameliorates Negative Gluten-Induced Impact on Physical Activities

    IMU-856 Ameliorates Negative Gluten-Induced Impact on Physical Activities Physical Activities, Mean Change Baseline to Day 14 Day 14 to Day 22 Day 14 to Day 29 Mean Change Mean Change Mean Change N N N Mean (SD) Mean (SD) Mean (SD) IMU-856 80 mg 14 0.11 (0.289) 11 -0.09 (0.302) 9 -0.11 (0.333) IMU-8

Immunic — Technical Presentation (May 2023) on 6ix